The medications create a metabolic environment where weight loss becomes dramatically easier, but dietary choices and physical activity still influence outcomes significantly
Any dose
Endpoints of Phase III ESSENCE trial, image source: Novo Nordisk official website These findings clearly show that semaglutide 2.4 mg not only promotes resolution of steatohepatitis but also significantly improves existing liver fibrosis, providing a powerful therapeutic option to slow or halt MASH progression
It is a potent intracellular antioxidant, as important as L-glutathione
What GLP-1s do in your body: Stimulate insulin release from pancreatic beta cells Slow gastric emptying, which reduces appetite Get metabolized primarily by the liver Are cleared partially through kidney function Have unknown long-term effects on thyroid C-cells Nearly half of patients stop GLP-1 therapy within the first year
Intermittent fasting works through a different set of mechanisms, shifting fuel utilization, improving insulin sensitivity, and triggering cellular cleanup processes